Aligos Therapeutics (NASDAQ:ALGS) Upgraded at UBS Group

Aligos Therapeutics (NASDAQ:ALGS) was upgraded by analysts at UBS Group to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

Several other research analysts have also commented on the company. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Aligos Therapeutics in a research report on Friday, September 12th. Wall Street Zen downgraded shares of Aligos Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Aligos Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $35.00.

Aligos Therapeutics Stock Performance

NASDAQ ALGS opened at $10.33 on Wednesday. The company has a market cap of $63.53 million, a PE ratio of -0.52 and a beta of 2.64. The firm’s 50 day moving average price is $9.27 and its 200-day moving average price is $9.22. Aligos Therapeutics has a 52-week low of $3.76 and a 52-week high of $37.12.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Thursday, November 6th. The company reported ($3.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.09) by ($0.95). The company had revenue of $0.74 million for the quarter, compared to analysts’ expectations of $0.50 million. Aligos Therapeutics had a negative return on equity of 39.35% and a negative net margin of 3,267.65%. On average, analysts forecast that Aligos Therapeutics will post -10.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aligos Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sio Capital Management LLC grew its stake in shares of Aligos Therapeutics by 85.9% during the second quarter. Sio Capital Management LLC now owns 335,937 shares of the company’s stock worth $2,422,000 after acquiring an additional 155,217 shares during the last quarter. Woodline Partners LP acquired a new stake in Aligos Therapeutics in the 1st quarter worth approximately $2,602,000. Readystate Asset Management LP grew its position in Aligos Therapeutics by 48.5% during the 3rd quarter. Readystate Asset Management LP now owns 203,113 shares of the company’s stock worth $1,991,000 after purchasing an additional 66,331 shares during the last quarter. Vanguard Group Inc. grew its position in Aligos Therapeutics by 22.8% during the 3rd quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock worth $1,683,000 after purchasing an additional 31,913 shares during the last quarter. Finally, Two Sigma Investments LP increased its stake in Aligos Therapeutics by 223.0% during the 3rd quarter. Two Sigma Investments LP now owns 38,995 shares of the company’s stock valued at $382,000 after purchasing an additional 26,922 shares in the last quarter. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.